FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18,...
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing...
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and...
CARAC (fluorouracil cream), 0.5% . ...
NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of...
· Collaboration strengthens Boehringer’s pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or...
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board...
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell...
Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30,...
– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK,...
-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini,...
Company expects to complete BLA submission in the fourth quarter of 2025NOVATO, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx...
EG America, 6th Largest U.S. Convenience Chain, Bolstering 1,600+ High-Traffic Locations NationwideWESTBROOK, Maine, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Synergy...
FORT MILLS, S.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device...
Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and...
ROCKVILLE, Md., Aug. 18, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today...
Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”) issued the following...
ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including...
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor...
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)...